How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
While many AIs used to assist drug discovery are provided by big tech companies at a cost, a small US and China-based techbio ...
Most security teams think of NTFS junctions and symbolic links as niche file system features. They let one directory point to another, like a shortcut that the OS treats as real. They exist for ...
Ben Taylor, CFO of Recursion, here with us. Thanks so much for joining us. Sure. Great. And first of all, thanks for having us here, Tommie. This is always a terrific conference and great to be here.
Recursive Self-Improvement Now Has a Co-Evolving Evaluator: Cambridge-NVIDIA Paper Raises the Stakes
Recursive self-improvement AI now has a co-evolving evaluator: a Cambridge and NVIDIA preprint introduces the Red Queen Gödel ...
AI isn't failing because models are bad; it's struggling because most industries lack the structured workflows needed to ...
USA News Group, There is a growing consensus in artificial intelligence that the models themselves are becoming interchangeable, and that lasting competitive advantage is shifting away from the model ...
The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, ...
Autonomous AI post-training reached frontier scale for the first time: NVIDIA researchers published a paper showing an AI ...
Vitalik Buterin outlined the updated Lean Ethereum roadmap, a 3-to-4-year plan covering quantum resistance, 10,000 TPS ...
Everyone is racing to point powerful AI models at drug discovery. A growing camp argues the real prize is the layer beneath the models — the connected biological knowledge they reason over — and that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results